Additional file 1. Table composed of three separate sheets. The first sheet reports the analyzed diseases with the corresponding number of disease-causing genes. The second sheet reports the analyzed
Supplementary Table 4. List of Compounds that are predicted to reverse the monocytes signature in SLE, derived from the L1000CDS2 platform-based drug repurposing analysis.
Characterization and preclinical in silico safety assessment of three virulent bacteriophages targeting carbapenem-resistant uropathogenic Escherichia coli
